Display options
Cite
Kabir A, Pazouki A, Jafari M, et al. Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases. Iran Biomed J. 2017;21(3):197-202doi: 10.18869/acadpub.ibj.21.3.197.
Kabir, A., Pazouki, A., Jafari, M., Mokhber, S., Vaziri, M., & Alavian, S. M. (2017). Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases. Iranian biomedical journal, 21(3), 197-202. https://doi.org/10.18869/acadpub.ibj.21.3.197
Kabir, Ali, et al. "Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases." Iranian biomedical journal vol. 21,3 (2017): 197-202. doi: https://doi.org/10.18869/acadpub.ibj.21.3.197
Kabir A, Pazouki A, Jafari M, Mokhber S, Vaziri M, Alavian SM. Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases. Iran Biomed J. 2017 May;21(3):197-202. doi: 10.18869/acadpub.ibj.21.3.197. Epub 2017 Feb 14. PMID: 27805073; PMCID: PMC5392223.
Copy Download .nbib Format: NLM
Share it on

Iran Biomed J. 2017 May;21(3):197-202. doi: 10.18869/acadpub.ibj.21.3.197. Epub 2017 Feb 14.

Comparing Anti-hepatitis B Antibody Level in Iranian Obese or Overweight with Non-obese Cases.

Iranian biomedical journal

Ali Kabir, Abdolreza Pazouki, Motahareh Jafari, Somayye Mokhber, Mohammad Vaziri, Seyed Moayed Alavian

Affiliations

  1. Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran.
  2. Middle East Liver Disease Center, Tehran, Iran.

PMID: 27805073 PMCID: PMC5392223 DOI: 10.18869/acadpub.ibj.21.3.197

Abstract

BACKGROUND: There is a controversy about the relation between anti-hepatitis B (anti-HBs) antibody level and obesity. We designed this study to compare the vaccine efficacy in obese/overweight and non-obese cases.

METHODS: In this cross-sectional study, 242 obese/overweight and 85 non-obese individuals were participated. Cases were selected from a referral clinic for obesity and a referral hepatology clinic, both in Tehran, Iran.

RESULTS: Obese cases had lower percentage of liver diseases (66.9% vs. 100%, P<0.001) but higher hepatitis B vaccination history (74.9% vs. 51.2%, P<0.001). Median±inter-quartile range of anti-HBs titer in obese cases was significantly lower than controls (48.5±194.5 vs. 100±557.6, P=0.012).

CONCLUSION: The level of anti-HBs surface antigen antibody's titer in obese cases without liver disease is lower than control group. Therefore, a suitable strategy is needed to overcome this problem, which can be the use of longer needles for vaccination.

Keywords: Hepatitis B vaccines; Obesity; Liver diseases; Immunosuppressive agent

References

  1. N Engl J Med. 1985 Aug 29;313(9):579-80 - PubMed
  2. Lancet. 2000 Feb 12;355(9203):561-5 - PubMed
  3. PLoS One. 2013 Dec 11;8(12):e82779 - PubMed
  4. Vaccine. 1989 Oct;7(5):425-30 - PubMed
  5. BioDrugs. 1998 Aug;10(2):137-58 - PubMed
  6. Sci Rep. 2016 Jun 21;6:27251 - PubMed
  7. J Diabetes Metab Disord. 2014 Dec 23;13(1):121 - PubMed
  8. Lupus. 2007;16(8):651-6 - PubMed
  9. Biologicals. 2007 Apr;35(2):115-22 - PubMed
  10. JAMA. 1993 Dec 22-29;270(24):2931-4 - PubMed
  11. Am J Prev Med. 1998 Jul;15(1):1-8 - PubMed
  12. MMWR Recomm Rep. 2006 Dec 1;55(RR-15):1-48 - PubMed
  13. Hum Vaccin. 2008 Sep-Oct;4(5):379-83 - PubMed
  14. World J Gastroenterol. 2013 Mar 7;19(9):1349-53 - PubMed
  15. BMJ. 2006 Sep 16;333(7568):571 - PubMed
  16. JAMA. 1985 Dec 13;254(22):3187-9 - PubMed
  17. JAMA. 1997 Jun 4;277(21):1709-11 - PubMed
  18. Epidemiol Mikrobiol Imunol. 2007 Aug;56(3):119-28 - PubMed
  19. BMJ. 2000 Nov 18;321(7271):1237-8 - PubMed
  20. World J Gastroenterol. 2014 Aug 14;20(30):10383-94 - PubMed

Publication Types